


# #26B-18 Vaccine to control bovine paratuberculosis



**For every evident clinical case (Stage III) of Paratuberculosis, between 15-25 infected animals may be disseminating the disease**

Paratuberculosis is an infectious and chronic disease. It mainly affects the small intestine of all ruminants. Paratuberculosis is caused by *Mycobacterium avium* subsp. (MAP), which is **disseminated worldwide**.

**Vaccination is a key tool to increase herd productivity.** Control of Paratuberculosis based on vaccination campaigns enables to control disease propagation, reduce infection risk, reduce herd mortality, **and avoid future economic losses.**

The **INTA Biotechnology Institute** has developed a **vaccine, from a local inactivated strain**, which has proven effective in protecting against paratuberculosis infection in a murine model.

## ADVANTAGES:

- Efficacy in inducing a protective immune response.
- Vaccine formulation from a local strain.
- Better protection than the one provided by commercial vaccines.

## TECHNOLOGY READINESS LEVEL:

Vaccine formulation that protects against *Mycobacterium avium* subsp. *paratuberculosis*. Characterization, efficacy, and protection against infection have been evaluated in a murine model. The immune response was achieved in bovine cattle and the interference test with the bovine Tuberculosis diagnosis was completed. Field potency tests are required.

**INTELLECTUAL PROPERTY RIGHTS STATUS:** Vaccine formulation that qualifies for trade secrecy protection.

DNA de Vinculación Tecnológica y Relaciones Institucionales - National Coordination Office for Technological Cooperation and Institutional Relations, INTA . Intellectual Property Department-Technological Antenna  
Dr. Mariana Nanni [nanni.mariana@inta.gob.ar](mailto:nanni.mariana@inta.gob.ar)

